Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug FILSPARI [2][4]. Group 1: Company Overview - Travere Therapeutics, Inc. is facing scrutiny after its shares were halted from trading due to a more than 30% decline in intraday trading on January 13, 2026 [2]. - The U.S. FDA has set a new PDUFA target action date of April 13, 2026, for the supplemental New Drug Application for FILSPARI, indicating that additional data is required to assess clinical benefits [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the FDA review extension and if prior communications were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the stock price decline [4]. Group 3: Investor Eligibility - Any investor who purchased common stock of Travere Therapeutics and experienced a loss may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and its executives made materially false or misleading statements or omitted important information regarding its business and operations [1][2] Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3] - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for providing the most monetary relief to investors [3]

Core Insights - Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. complied with federal securities laws following the FDA's extension of the review timeline for its supplemental New Drug Application for FILSPARI® in focal segmental glomerulosclerosis, which led to a drop in the company's stock price [1] Company Summary - Travere Therapeutics, Inc. disclosed on January 13, 2026, that the FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI® [1] - The announcement resulted in a decline in the company's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Viewpoint - Shares of Travere Therapeutics (TVTX) declined by 14.6% following the FDA's announcement to extend the review timeline for the supplemental new drug application (sNDA) for Filspari in the FSGS indication by three months, with a new decision date set for April 13, 2026 [1][7]. FDA Review Extension - The FDA extended the review timeline after Travere submitted additional information to better define the clinical benefit of Filspari, classifying these submissions as a major amendment to the sNDA [2]. - No new safety or manufacturing data was requested by the FDA for Filspari [2]. Product Information - Filspari is currently approved to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression [3]. - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S. and a similar number in the EU, characterized by progressive kidney scarring and proteinuria [5][8]. - If approved for FSGS, Filspari would be the first FDA-approved therapy for this condition, addressing podocyte injury, a critical factor in FSGS progression [8]. Market Performance - Over the past six months, Travere Therapeutics' shares have increased by 72.1%, outperforming the industry average increase of 20.4% [4]. Financial Projections - Preliminary sales for Q4 2025 are expected to be around $127 million, with full-year 2025 net product sales projected at approximately $410 million in the U.S. [10]. - Preliminary U.S. net product sales of Filspari for Q4 2025 are estimated at $103 million, reflecting a 108% year-over-year increase, with full-year sales around $322 million [11]. Partnerships and Future Plans - In October 2025, Travere received a $40 million milestone payment from CSL Vifor after achieving market access milestones, with further payments expected tied to additional market access and sales [12]. - The company plans to continue building clinical evidence to support Filspari as a foundational treatment for IgAN through ongoing clinical studies, with the potential label expansion for FSGS likely to boost sales in 2026 [13].

Core Viewpoint - Travere Therapeutics experienced a significant decline in stock value due to a regulatory setback regarding its leading drug candidate, Filspari, which is under FDA review for a kidney disorder [1][6]. Group 1: Regulatory Developments - The FDA has extended the review timeline for Travere's New Drug Application for Filspari, with a new target action date set for April 13, three months later than the original deadline of January 13 [2][3]. - This extension follows the company's submission of additional information requested by the FDA to better characterize the clinical benefits of Filspari [3]. Group 2: Market Reaction - Following the news of the FDA's extension, Travere's shares fell nearly 15% in a single day as investors reacted negatively to the delay [1]. - The market's reaction may be seen as an overreaction, as delays due to "major amendments" are not uncommon in the regulatory process [4]. Group 3: Drug Significance - Filspari, if approved for focal segmental glomerulosclerosis (FSGS), would be the first drug approved for this disorder, adding significant value to Travere's portfolio [3]. - The drug is already FDA-approved for treating IgA nephropathy, indicating its potential in the renal therapeutic area [3].

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and its executives made materially false and/or misleading statements or omitted important information regarding its business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024 alone, which is more than the next five law firms combined [3].

Company Overview - Travere Therapeutics (TVTX) experienced a significant decline in share price following the announcement of a delay in the FDA approval for its drug Filspari, intended for treating focal segmental glomerulosclerosis (FSGS) [3] - The FDA is now expected to make a decision on Filspari by April 13, which is a postponement from the original date of January [3] Market Reaction - The market reacted negatively to the news, leading to a crash in Travere Therapeutics' shares as investors processed the implications of the delay [3] - Despite the setback, Travere Therapeutics has been highlighted as a stock that has doubled in value in 2025, indicating previous strong performance prior to the announcement [6] Future Outlook - The company is under scrutiny as it approaches the new FDA decision date, with potential implications for its market position and investor sentiment [3][6] - Travere Therapeutics has received a composite rating upgrade, suggesting some analysts still see potential in the stock despite the recent challenges [8]

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in share price after the FDA extended the review timeline for a key drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the decline in share value [4]. Group 3: Investor Eligibility - Any individual who purchased common stock of Travere Therapeutics and has experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their investment [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - The U.S. FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application for FILSPARI® in the treatment of focal segmental glomerulosclerosis, with a new target action date set for April 13, 2026 [1] Group 1 - The FDA's extension follows the recent submission of additional responses requested to further characterize the clinical benefit of FILSPARI® [1]

Market Performance - U.S. stocks showed mixed performance with the Dow Jones index falling over 200 points, down 0.60% to 49,293.33, while the NASDAQ gained 0.17% to 23,773.29 and the S&P 500 dropped 0.08% to 6,971.95 [1] - In the energy sector, shares increased by 1.4%, while financial stocks decreased by 1.8% [1] Inflation Data - Inflation remained steady in December, with the Consumer Price Index rising 2.7% year over year, matching economist expectations and unchanged from November [2] - Monthly consumer prices increased by 0.3%, also in line with forecasts [2] Commodity Prices - Oil prices rose by 2.6% to $61.06, while gold increased by 0.1% to $4,620.80 [4] - Silver prices surged by 4.4% to $88.860, whereas copper fell by 0.1% to $6.0295 [4] European Market Trends - European shares were mixed, with the eurozone's STOXX 600 falling 0.08% and Spain's IBEX 35 Index rising 0.08% [5] - London's FTSE 100 slipped 0.03%, Germany's DAX gained 0.06%, and France's CAC 40 fell 0.14% [5] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei surging 3.10% and Hong Kong's Hang Seng Index gaining 0.90% [8] - Conversely, China's Shanghai Composite fell 0.64% and India's BSE Sensex decreased by 0.30% [8] Company-Specific Movements - Beyond Air Inc shares surged 172% to $2.39 following an acquisition agreement, potentially receiving up to $32.5 million [7] - Ambitions Enterprise Management Co LLC shares increased by 106% to $10.90 due to a year-over-year EPS increase [7] - TryHard Holdings Ltd shares rose by 77% to $40.96 after announcing a collaboration agreement and a $10 million share repurchase program [7] - Signing Day Sports Inc shares dropped 57% to $0.25 after announcing a public offering [7] - Travere Therapeutics Inc shares fell 32% to $23.16 following preliminary fourth-quarter financial results [7] - Wealthfront Corp shares decreased by 18% to $10.34 due to weak quarterly sales [7]